U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 8 of 8 results

Cortex fraxini, a famous Chinese herbal folk medicine, is used for the clinical treatment of hyperuricemia, arthritis, diarrhea, liver-protective. and bacillary dysentery. Fraxin, a main active component isolated from Cortex fraxini, possesses a vari...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In gout patients, Lesinurad lowe...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Topiroxostat was approved by Pharmaceuticals Medical Devices Agency of Japan (PMDA) on June 28, 2013. It was co-developed and marketed as Uriadec®/Topiloric® by Sanwa Kagaku Kenkyusho & Fuji Yakuhin. Topiroxostat is a xanthine oxidase inhibitor. ...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)


Levotofisopam is the S-enantiomer of racemic tofisopam Monotherapy with levotofisopam led to clinically meaningful reduction of Serum Uric Acid (SUA) in patients with hyperuricemia and gout. Treatment was generally well tolerated with 23% of the pati...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In gout patients, Lesinurad lowe...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In gout patients, Lesinurad lowe...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In gout patients, Lesinurad lowe...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Topiroxostat was approved by Pharmaceuticals Medical Devices Agency of Japan (PMDA) on June 28, 2013. It was co-developed and marketed as Uriadec®/Topiloric® by Sanwa Kagaku Kenkyusho & Fuji Yakuhin. Topiroxostat is a xanthine oxidase inhibitor. ...